Why the study?
Does daily recombinant growth hormone therapy improve adult height in GH-deficient children when started early?
Does daily recombinant growth hormone therapy improve adult height in GH-deficient children when started early?
Early initiation of daily recombinant growth hormone therapy in GH-deficient children before age 5 allows for full catch-up growth to target adult height.
Early GH start was associated with target adult height in this cohort; leaves open confirmation in randomized trials.
More than 30 years after its introduction, growth hormone (GH) treatment is well established in children with GH deficiency. Nevertheless, the long-term results of this therapy, expressed as height, are generally considered unsatisfactory. We report on results obtained in a group of GH-deficient children who were treated with daily injections of recombinant GH within the first 5 years of life and who reached an adult height very close to their target height. The full catch-up growth to the target height demonstrated in these patients suggests that replacement therapy should be started early and continued until adulthood. Height at onset of puberty is an important variable which might significantly influence the adult height. The significant and prolonged influence of birth weight on growth response to GH therapy underlines the important role of fetal growth in planning early treatment of GH-deficient children.
No takes yet. Share an insight, caveat, or question.
Bernasconi et al. (2000) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: